High-concentration antibodies
Antibody doses are large, but patients prefer a small injection they can give themselves at home. The answer is to pack a monoclonal antibody to very high concentration — often above 100 mg per mL — into a single prefilled syringe. At those concentrations molecules are crowded shoulder to shoulder, so two problems bite hard: the liquid turns syrupy and hard to push through a thin needle, and crowding accelerates aggregation. The buffer, sugar and polysorbate toolkit from earlier is tuned aggressively, sometimes with extra additives that thin the liquid, to make a high dose both stable and injectable.
Vaccines and adjuvants
A classic vaccine presents the immune system with an antigen — a weakened germ or a purified protein. But a purified antigen on its own is often a weak teacher. So vaccine formulation frequently adds an adjuvant: a substance that amplifies the immune response, letting a smaller antigen dose work harder and last longer. The oldest and most common adjuvants are aluminium salts, onto which the antigen is adsorbed; the antigen sits on the particle surface and is presented slowly to immune cells.
mRNA in a lipid nanoparticle
An mRNA vaccine solves a harder problem: naked mRNA is shredded by enzymes within minutes and is too large and charged to enter a cell on its own. The breakthrough was to wrap it in a lipid nanoparticle (LNP) — a tiny fatty sphere, an example of nanomedicine. The LNP protects the mRNA, carries it into the cell, and releases it so the cell can read the instructions and make the target protein. Building the particle is itself the formulation: a special ionisable lipid binds the mRNA and helps it escape inside the cell, while other lipids and a PEGylated lipid set the size and keep particles from fusing.
Even wrapped, the mRNA-LNP is fragile, which is why the first products demanded a deep-freeze cold chain. Freeze-drying these particles is hard — the ice can shear them apart — so much of the recent work has been on lyoprotectant systems and milder process conditions to make a fridge-stable, eventually a shelf-stable, mRNA medicine. It is a fitting finale: every theme of this track — fragility, stabilizers, surfactants, the freeze, the cold chain — converges in one tiny sphere.